ArticleBiochemistry and biophysics reports2025
Clinical significance of altered expression of mitochondrial genome-derived LncRNA LIPCAR in colorectal cancer.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence and mortality of colorectal cancer (CRC) are rising; therefore, understanding its molecular pathophysiology is necessary for identifying reliable diagnostic and therapeutic markers. Several studies corroborate the fact that the initiation and progression of various diseases, including cancers, are significantly influenced by the dysregulation of mitochondrial transcripts, such as lncRNAs encoded by the mitochondrial genome. This study is the first to examine the expression profile of LIPCAR in CRC and its correlation with clinicopathological parameters. Methods: In this work, 40 pairs of CRC tissues were obtained, including 40 tumor samples and 40 adjacent non-tumor samples. The SYBR green technique was applied in real-time PCR to analyze the expression profile of LIPCAR in CRC patients. Results: The findings indicated a significant downregulation of LIPCAR in tumor tissue samples compared to adjacent non-tumoral tissues (p-value<.05). Furthermore, no significant relationship between the patients' clinical data and decreased LIPCAR expression was found. Receiver Operating Characteristic (ROC) curve analysis revealed that LIPCAR had an area under the curve (AUC) of .75 (p-value <.0001), with a sensitivity of 87.5 % and a specificity of 57.5 % at a cutoff value of .094. Conclusion: The marked downregulation of LIPCAR expression suggests its critical involvement in the pathogenesis of CRC, potentially functioning as a tumor suppressor. Furthermore, LIPCAR may serve as a clinical biomarker for CRC patients. However, this hypothesis necessitates further validation through comprehensive functional studies conducted both in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.